文章基本信息

标题：Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study
本地全文：下载
作者：Hirofumi Hamano ; Chisato Mitsuhashi ; Yoshiko Suzuki 等
期刊名称：Biological and Pharmaceutical Bulletin
印刷版ISSN：0918-6158
电子版ISSN：1347-5215
出版年度：2021
卷号：44
期号：4
页码：478-484
DOI：10.1248/bpb.b20-00609
出版社：The Pharmaceutical Society of Japan
摘要：Patients who undergo multiple-day chemotherapy sessions experience hard-to-treat nausea and vomiting. Currently, there is no effective standard treatment for this condition. This study compared the preventive effect of first-generation 5-hydroxytryptamine 3 receptor antagonists (5-HT 3 RAs) and second-generation 5-HT 3 RAs palonosetron in multiple-day chemotherapy-induced nausea and vomiting. The design of this study was a retrospective case-control study of patients who received a five-day cisplatin-based chemotherapy and were treated with aprepitant, dexamethasone, granisetron, and ramosetron or palonosetron. The patients were divided into two groups: patients given granisetron and ramosetron (the first-generation group), and those given palonosetron (palonosetron group). The percentage of patients with a complete response or total control was assessed. They were divided into three phases: 0–216 h (overall phase), 0–120 h (remedial phase), and 120–216 h (after phase). The remedial phase was further divided into 0–24 h (early phase) and 24–120 h (later phase). Moreover, the nutritional status of each patient was assessed by noting the patients’ total calorie-intake per day and total parenteral nutrition. First-generation 5-HT 3 RAs and palonosetron were used for treatment in 18 and 28 patients, respectively. The complete response rate and caloric oral intake of the later phase were higher in the palonosetron group than in the first-generation group. We conclude that palonosetron treatment was more effective than first-generation 5-HT 3 RAs in controlling multiple-day chemotherapy-induced nausea and vomiting.
关键词：palonosetron;chemotherapy-induced nausea and vomiting;supportive care;5-hydroxytryptamine 3 antagonist;multiple-day chemotherapy